MAPT and Alzheimer disease: In cerebrospinal fluid (CSF), NPTX2 levels are decreased in individuals with mild cognitive impairment (MCI) and AD [8–10], and its inclusion improves the diagnostic performance of established AD biomarkers, such as the Aβ42/40 ratio and tau proteins [3, 11].